Key facts
- VIAN Therapeutics’s last known valuation is $7.0M.
- It has raised $1.3M; the latest was Seed Round ($1.0M) in Nov 2024.
- Notable investors include SOSV, IndieBio, Sand Hill Angels, Ulu Ventures, SeedFolio — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for VIAN Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for VIAN Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About VIAN Therapeutics
Developer of an early-stage biotechnology company intended to reduce the progression of cancer. The company specializes in making peptide drugs with enhanced efficacy, safety, and convenience, also working to reduce the progression of cancer and other angiogenesis-dependent diseases by inhibiting angiogenesis with a novel, potent, multi-target, orally active drug, it replaces invasive injections for conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME), enabling patients with ophthalmology and oncology-related diseases to live a healthy life.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2023
- Website
- viantx.com/
- Ownership
- Privately Held (backing)
VIAN Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VIAN Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VIAN Therapeutics in its N-PORT filings yet. We sweep new filings monthly.